novartis q4 - Search News

Novartis beats Q4 earnings consensus

YAHOO!Finance · 17h

Novartis Q4 Earnings: Revenue And EPS Beat, CEO Dismisses Entresto Patent Expiration Worries

Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported fourth-quarter adjusted earnings per share of $1.98, beating the street view of $1.

Novartis beats Q4 earnings consensus as drug sales surge

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer multiple sclerosis drug Kesimpta exceeded forecasts.

BioSpace · 15h

Novartis Eyes More Bolt-On Deals in 2025 as Q4 Earnings Easily Beat Consensus

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

13hon MSN

Novartis has cash for a big pharma deal—but here’s why it’s not buying

Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...

17h

Novartis reports Q4 core EPS $1.98 vs. $1.53 last year

Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...

19h

Novartis CEO says U.S. exit from global health programmes to affect millions

The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results